PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Prognostic value of pretreatment standardized uptake value of F-18-fluorodeoxyglucose PET in patients with gastric cancer: a meta-analysis.

Abstract F-18- fluorodeoxyglucose Positron emission tomography ((18)FDG-PET) has been widely used in clinical practice. However, the prognostic value of the pretreatment standardized uptake value (SUV) for patients with gastric cancer remains controversial.
PMID
Related Publications

Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project.

Prognostic significance of parameters from pretreatment (18)F-FDG PET in hepatocellular carcinoma: a meta-analysis.

Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis.

Predictive value of pretreatment metabolic activity measured by fluorodeoxyglucose positron emission tomography in patients with metastatic advanced gastric cancer: the maximal SUV of the stomach is a prognostic factor.

Preoperative Standardized Uptake Value of Metastatic Lymph Nodes Measured by 18F-FDG PET/CT Improves the Prediction of Prognosis in Gastric Cancer.

Authors

Mayor MeshTerms
Keywords

Gastric cancer

Meta-analysis

Positron emission tomography

Prognosis

Standardized uptake value

Journal Title bmc cancer
Publication Year Start




PMID- 28415990
OWN - NLM
STAT- MEDLINE
DA  - 20170418
DCOM- 20170418
LR  - 20170421
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 17
IP  - 1
DP  - 2017 Apr 17
TI  - Prognostic value of pretreatment standardized uptake value of
      F-18-fluorodeoxyglucose PET in patients with gastric cancer: a meta-analysis.
PG  - 275
LID - 10.1186/s12885-017-3271-z [doi]
AB  - BACKGROUND: F-18- fluorodeoxyglucose Positron emission tomography (18FDG-PET) has
      been widely used in clinical practice. However, the prognostic value of the
      pretreatment standardized uptake value (SUV) for patients with gastric cancer
      remains controversial. METHODS: Major databases were systematically searched. The
      quality of the included studies was assessed using the Newcastle-Ottawa scale;
      the PET protocols were also evaluated. The pooled hazard ratio (HR) for overall
      survival (OS) and recurrence-free survival (RFS) were used to estimate the effect
      size. Data from the included studies were analyzed using Review Manager Software 
      version 5.2. RESULTS: Eight studies with 1080 patients were included. The pooled 
      HR for OS of six studies including 672 patients was 1.72 (95% CI [1.28-2.3], p = 
      0.0004, I2 = 0%), indicating that patients with high SUVs may have poor
      prognosis. The pooled HR for RFS was 1.70 (95% CI [1.20-2.39], p = 0.003, I2 =
      0%). Subgroup analysis based on the cutoff values determining method indicated
      that the receiver operating characteristic (ROC) method could better define the
      cutoff value. Subgroup analysis based on the therapeutic strategies used
      subsequently indicated the significant prognostic value of SUV. CONCLUSION: In
      conclusion, our meta-analysis indicated that pretreatment SUV in primary lesions 
      can be an important prognostic factor for overall survival and recurrence-free
      survival in patients with gastric cancer. High SUVs may indicate poor prognosis.
FAU - Wu, Zhonghua
AU  - Wu Z
AD  - Department of Surgical Oncology and General Surgery, The First Affiliated
      Hospital of China Medical University, 155 North Nanjing Street, Heping District, 
      Shenyang, 110001, People's Republic of China.
FAU - Zhao, Junhua
AU  - Zhao J
AD  - Department of Surgical Oncology and General Surgery, The First Affiliated
      Hospital of China Medical University, 155 North Nanjing Street, Heping District, 
      Shenyang, 110001, People's Republic of China.
FAU - Gao, Peng
AU  - Gao P
AD  - Department of Surgical Oncology and General Surgery, The First Affiliated
      Hospital of China Medical University, 155 North Nanjing Street, Heping District, 
      Shenyang, 110001, People's Republic of China.
FAU - Song, Yongxi
AU  - Song Y
AD  - Department of Surgical Oncology and General Surgery, The First Affiliated
      Hospital of China Medical University, 155 North Nanjing Street, Heping District, 
      Shenyang, 110001, People's Republic of China.
FAU - Sun, Jingxu
AU  - Sun J
AD  - Department of Surgical Oncology and General Surgery, The First Affiliated
      Hospital of China Medical University, 155 North Nanjing Street, Heping District, 
      Shenyang, 110001, People's Republic of China.
FAU - Chen, Xiaowan
AU  - Chen X
AD  - Department of Surgical Oncology and General Surgery, The First Affiliated
      Hospital of China Medical University, 155 North Nanjing Street, Heping District, 
      Shenyang, 110001, People's Republic of China.
FAU - Ma, Bin
AU  - Ma B
AD  - Department of Surgical Oncology and General Surgery, The First Affiliated
      Hospital of China Medical University, 155 North Nanjing Street, Heping District, 
      Shenyang, 110001, People's Republic of China.
FAU - Wang, Zhenning
AU  - Wang Z
AD  - Department of Surgical Oncology and General Surgery, The First Affiliated
      Hospital of China Medical University, 155 North Nanjing Street, Heping District, 
      Shenyang, 110001, People's Republic of China. [email protected]
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20170417
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - IM
MH  - Disease-Free Survival
MH  - Fluorodeoxyglucose F18/*pharmacokinetics
MH  - Humans
MH  - Positron-Emission Tomography/*methods
MH  - Prognosis
MH  - Radiopharmaceuticals/*pharmacokinetics
MH  - Stomach Neoplasms/*diagnostic imaging/*metabolism
PMC - PMC5392988
OTO - NOTNLM
OT  - *Gastric cancer
OT  - *Meta-analysis
OT  - *Positron emission tomography
OT  - *Prognosis
OT  - *Standardized uptake value
EDAT- 2017/04/19 06:00
MHDA- 2017/04/19 06:01
CRDT- 2017/04/19 06:00
PHST- 2016/08/18 [received]
PHST- 2017/04/07 [accepted]
AID - 10.1186/s12885-017-3271-z [doi]
AID - 10.1186/s12885-017-3271-z [pii]
PST - epublish
SO  - BMC Cancer. 2017 Apr 17;17(1):275. doi: 10.1186/s12885-017-3271-z.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>